Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cognitive impairment in multiple sclerosis].

Iwona Karlińska1, Krzysztof Selmaj

  • 1Katedra i Klinika Neurologii, Uniwersytet Medyczny w Łodzi. Ikar@afazja.am.lodz.pl

Neurologia I Neurochirurgia Polska
|May 5, 2005
PubMed
Summary

Cognitive dysfunctions, affecting memory and attention, are common in multiple sclerosis (MS). Brain lesions and atrophy correlate with these cognitive impairments in MS patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis.

Frontiers in immunology·2026
Same author

Summary of Research: Cognition and Employment Status of People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-Year CLARIFY-MS Study.

Neurology and therapy·2026
Same author

Correction: Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two‑year Phase IV CLARIFY‑MS Study.

Neurology and therapy·2026
Same author

Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials.

Lancet (London, England)·2026
Same author

A new, glycoengineered form of anti-CD20 monoclonal antibody, in treatment of multiple sclerosis.

Therapeutic advances in neurological disorders·2026
Same author

Novel homozygous <i>SYNE1</i> missense variant in late onset autosomal recessive cerebellar ataxia 1: a case report.

Therapeutic advances in neurological disorders·2026

Area of Science:

  • Neurology
  • Neuropsychology

Context:

  • Cognitive dysfunctions are prevalent in multiple sclerosis (MS), impacting 40-65% of patients.
  • Deficits commonly manifest in memory, attention, processing speed, executive functions, and abstract reasoning.

Purpose:

  • To review cognitive dysfunctions in MS.
  • To correlate these deficits with clinical presentation and neuroimaging findings.

Summary:

  • Cognitive impairments in MS are widespread, affecting key cognitive domains.
  • The severity and type of cognitive dysfunction vary with clinical course, disease duration, disability, and treatment.
  • Neuroimaging, including MRI, reveals correlations between cognitive deficits and lesion load, normal-appearing brain tissue damage, and brain atrophy.

Impact:

  • Highlights the significant impact of cognitive impairment on MS patients' lives.
  • Provides insights into the neuropathological underpinnings of cognitive deficits in MS.
  • Informs clinical assessment and management strategies for MS-related cognitive issues.

Related Experiment Videos